SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

In the showdown between left atrial appendage (LAA) closure devices, the Amplatzer Amulet outperformed Watchman for peridevice leaks (PDL) in one trial longer term but not in another. At 12 months of ...

(UPDATED) In patients undergoing left atrial appendage (LAA) occlusion, the Amplatzer Amulet device (Abbott) provides better closure as well as noninferior safety and effectiveness compared with the ...

NEW BERN, N.C. (WNCT) — CarolinaEast Medical Center has made reached a huge milestone by being the first hospital in a 100-mile radius to offer the Amulet procedure. The first procedure was done by Dr ...

PARIS, France—Left atrial appendage (LAA) occlusion with the Amplatzer Amulet (Abbott) reduces the risk of ischemic stroke in real-world use through 2 years, for the most part without the need for ...

PHOENIX (3TV/CBS 5)-- Abrazo Arizona Heart Hospital announced Tuesday a new heart procedure, becoming the first facility in the Phoenix area to offer it. The procedure is with the Amulet device that ...

Heart doctors at OhioHealth Mansfield Hospital this month celebrated their 500th procedure to help reduce the risk of stroke in patients with atrial fibrillation. The milestone left atrial appendage ...

Abbott announced that the US Food and Drug Administration (FDA) approved the company's Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk ...

Abbott's Amplatzer Amulet provided superior left atrial appendage (LAA) closure over the old-guard Watchman (Boston Scientific) device but failed to significantly cut stroke or bleeding rates in ...